Completed PHASE4 INTERVENTIONAL NCT00043901

Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Evaluation of Lamotrigine Adjunctive Therapy in Subjects Wtih Primary Generalized Tonic-Clonic Seizures

Sponsor: GlaxoSmithKline

Conditions Epilepsy, Tonic-Clonic

Interventions lamotrigine

Updated 7 times since 2017 Last updated: Mar 31, 2017 Started: Dec 1, 2000 Primary completion: Nov 1, 2003 Completion: Mar 1, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00043901, this PHASE4 trial focuses on Epilepsy, Tonic-Clonic and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2000, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

May 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — May 2017 [monthly]

Completed PHASE4

First recorded

Dec 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alabaster, United States , Albany, United States , Arlington, United States , Asheville, United States , Atlanta, United States , Augusta, United States , Bakersfield, United States , Baltimore, United States , Bennington, United States , Boise, United States and 66 more locations